A survey on the efficacy and tolerability of micronized fenofibrate in patients with dyslipidemia / 中华医学杂志(英文版)
Chinese Medical Journal
;
(24): 840-843, 2003.
Article
in English
| WPRIM
| ID: wpr-294219
ABSTRACT
<p><b>OBJECTIVE</b>To demonstrate the clinical efficacy of micronized fenofibrate on mildly-moderately elevated LDL-C levels and reduced HDL-C levels.</p><p><b>METHODS</b>During 1998 - 1999, 2358 patients with type IIa, IIb and IV hyperlipidemia were monitored in 16 cities in China. They were treated daily with micronized fenofibrate (micronized lipanthyl) 200 mg for 8 weeks. Lipid levels before and after the treatment were measured and analyzed.</p><p><b>RESULTS</b>Micronized fenofibrate significantly increased HDL-C levels by 12.7%, the effect being inversely correlated to the baseline level of HDL-C. Out of the total patient population, a baseline level of HDL-C < 1.0 mmol/L was found in 837 patients amongst this group, 510 patients (60.9%) were observed to have an increase in the level of HDL-C to > 1.0 mmol/L with a mean of 1.3 mmol/L, after 8-week micronized fenofibrate therapy. Furthermore, the mean LDL-C level decreased by 15.9% following an 8-week treatment of micronized fenofibrate, an effect positively correlated to the baseline level of LDL. In general, all patients tolerated the drug comfortably.</p><p><b>CONCLUSIONS</b>Short-term treatment of micronized fenofibrate in patients with dyslipidemia significantly increases HDL-C level and reduces mildly-moderately elevated LDL-C level. As expected, it also reduces triglyceride levels.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Fenofibrate
/
Blood
/
Therapeutic Uses
/
Drug Therapy
/
Hyperlipidemias
/
Cholesterol, HDL
/
Cholesterol, LDL
/
Hypolipidemic Agents
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
Language:
English
Journal:
Chinese Medical Journal
Year:
2003
Type:
Article
Similar
MEDLINE
...
LILACS
LIS